Alnylam Pharmaceuticals
As of the edition of 20 October 2026, Alnylam Pharmaceuticals runs 21 drugs, 7 of them marketed; it is on route A at 1 target and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 12 |
| Went quiet | 2 |
| Total | 21 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Patisiran | none listed | 0 |
| Lumasiran | Ends 2038 (patent) | 3 |
| Givosiran | none listed | 1 |
| Vutrisiran | none listed | 0 |
| Givosiran sodium | Ends 2034 (patent) | 1 |
| Patisiran sodium | Ends 2035 (patent) | 0 |
| Vutrisiran sodium | Ends 2036 (patent) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 4 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Alnylam Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 27 trials led
- Inherited and neonatal: 20 trials led
- Heart and blood vessels: 15 trials led